Halozyme Therapeutics Revenue and Competitors

We are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to cancer, PEGPH20 may help make existing treatments more effective by allowing therapies to reach the tumor. We are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly, for our ENHANZE drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. This technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details. We are Halozyme.

keywords:Biotechnology,Cleantech,Healthcare,Marketing,Medical Diagnostics,Pharmaceuticals,Wind Power